Kathleen Wortham

Medicine · Health Sciences

16h-index927citations31works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(7), Immunotherapy and Immune Responses(3), Cell Adhesion Molecules Research(3), Radiopharmaceutical Chemistry and Applications(3), T-cell and B-cell Immunology(2)

Publications31 total

Data from Targeting the Lymphotoxin-β Receptor with Agonist Antibodies as a Potential Cancer Therapy
2023Open Access
Supplementary Tables 1-3, Figure 1 from Targeting the Lymphotoxin-β Receptor with Agonist Antibodies as a Potential Cancer Therapy
2023Open Access
Supplementary Tables 1-3, Figure 1 from Targeting the Lymphotoxin-β Receptor with Agonist Antibodies as a Potential Cancer Therapy
2023Open Access
Data from Targeting the Lymphotoxin-β Receptor with Agonist Antibodies as a Potential Cancer Therapy
2023Open Access
Abstract B222: Dicer substrate siRNAs to MYC, B-catenin, and other target genes effectively induce in vivo target gene knockdown and tumor inhibition.
Molecular Cancer Therapeutics·2013· 1 cited
Knockdown of β-catenin with Dicer-Substrate siRNAs Reduces Liver Tumor Burden In vivo
Molecular Therapy·2013· 57 citedOpen Access
The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models
Cancer Biology & Therapy·2012· 27 citedOpen Access
Development of an Fn14 agonistic antibody as an anti-tumor agent
mAbs·2011· 48 citedOpen Access
An antibody–cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours
European Journal of Cancer·2011· 42 cited
Stable IgG-like Bispecific Antibodies Directed toward the Type I Insulin-like Growth Factor Receptor Demonstrate Enhanced Ligand Blockade and Anti-tumor Activity
Journal of Biological Chemistry·2010· 38 citedOpen Access
Protective Effect of BG9928, an Adenosine Receptor Antagonist, against Cisplatin‐Induced Acute Renal Injury in Rats: Comparison with Furosemide
The FASEB Journal·2009
Consultatns for the American Journal of Nephrology 2009
American Journal of Nephrology·2009Open Access
Protective Effect of Tonapofylline (BG9928), an Adenosine A<sub>1</sub> Receptor Antagonist, against Cisplatin-Induced Acute Kidney Injury in Rats
American Journal of Nephrology·2009· 25 cited
Subject Index Vol. 30, 2009
American Journal of Nephrology·2009Open Access
Contents Vol. 30, 2009
American Journal of Nephrology·2009
Blockade of A1 adenosine receptors with BG9928 prevents acute renal injury in rats
European Journal of Heart Failure Supplements·2008
Targeting the Lymphotoxin-β Receptor with Agonist Antibodies as a Potential Cancer Therapy
Cancer Research·2006· 116 citedOpen Access
Design, Synthesis, and Analysis of a Polyethelene Glycol-Modified (PEGylated) Small Molecule Inhibitor of Integrin α4β1 with Improved Pharmaceutical Properties
Journal of Pharmacology and Experimental Therapeutics·2005· 19 cited
An Assessment of the Mechanistic Differences Between Two Integrin α4β1 Inhibitors, the Monoclonal Antibody TA-2 and the Small Molecule BIO5192, in Rat Experimental Autoimmune Encephalomyelitis
Journal of Pharmacology and Experimental Therapeutics·2003· 60 cited
The Effect of Ibuprofen on Microvascular Thrombosis in an Experimental Rabbit Model
Annals of Plastic Surgery·1993· 50 cited
page 1 of 2Next →

Frequent Co-authors

Doreen LePage(7), Véronique Bailly(6), Ellen A. Garber(6), Mitchell E. Reff(6), Alan Gill(6), Barry Ticho(6), E. Whalley(6), Judith J. Petry(5), Matvey Lukashev(5), Cheryl A. Wilson(5), Alex Lukashin(5), Apinya Ngam-ek(5), Weike Zeng(5), Norman Allaire(5), Steve Perrin(5), Kendall T. Szeliga(5), Cindy Bottiglio(5), Jane Ding(5), Linda G. Griffith(5), Glenna Heaney(5)